REMARKS

Claims 46 and 48-79 have been canceled without prejudice to their inclusion in a continuing application.

Claims 47 and 80-82 have been replaced by claims 83-91 in view of the Examiner's objection to said claims as being dependent upon rejected claims and the Examiner's statement that pharmaceutical compositions comprising amylin or a mixture of amylin and insulin, as set forth in the above claims, are allowable (September 13, 1991 Office Action at page 4).

The Specification has been amended to more precisely capsule the article referenced at page 2. No new matter has been added.

CONCLUSION

For reasons set forth above, Applicant submits that his pending claims are in condition for allowance and seeks an early Notice thereof. Should there be any issues or questions, the Examiner is encouraged to telephone the undersigned in order that they may be promptly resolved.

Respectfully submitted,

Bradford J. Duft

Registration No. 32,219

LYON & LYON

611 W. Sixth Street

Suite 3400

Los Angeles, CA 90017

(619) 552-8400